CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Ticagrelor

Ticagrelor

Last Updated: June 8, 2010

Result type: Reports

Project Number: SR0203-000

Product Line: Reimbursement Review

Generic Name: Ticagrelor

Brand Name: Brilinta

Manufacturer: AstraZeneca Canada Inc

Therapeutic Area: Acute Coronary Syndromes

Indications: Acute Coronary Syndromes (ACS)

Submission Type: Initial

Project Status: Cancelled

Ticagrelor

Files